Abuse deterrence is one way drug manufacturers can make opioid analgesics stand out in the highly genericized and crowded market for pain, but gaining FDA approval for abuse-deterrence claims and demonstrating the value of these products has proven challenging.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?